<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Individuals with homozygous deficiency in <z:chebi fb="0" ids="17755">cystathionine</z:chebi>-beta-synthase (CBS) develop high levels of <z:chebi fb="0" ids="17230">homocysteine</z:chebi> in plasma, a condition known as homocysteinuria </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001249'>Mental retardation</z:hpo> ensues with <z:hpo ids='HP_0011420'>death</z:hpo> in teens; the heterozygous live normally but develop vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> and <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) in later part of life </plain></SENT>
<SENT sid="2" pm="."><plain>The treatment with muscimol, a gamma amino <z:chebi fb="4" ids="30772">butyric acid</z:chebi> receptor-A (<z:chebi fb="3" ids="16865">GABA</z:chebi>(A)) <z:chebi fb="4" ids="48705">agonist</z:chebi>, mitigates the AD syndrome and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We tested the hypothesis that <z:chebi fb="0" ids="17230">homocysteine</z:chebi> (<z:chebi fb="0" ids="17230">Hcy</z:chebi>) antagonizes the <z:chebi fb="3" ids="16865">GABA</z:chebi>(A) receptor and behaves as an excitotoxic neurotransmitter that causes blood brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) permeability and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:chebi fb="2" ids="33602">BBB</z:chebi> permeability was measured by infusing Evan's blue dye (2% in saline 5 ml/kg concentration) in CBS-/+, <z:chebi fb="3" ids="16865">GABA</z:chebi>(A)-/-, CBS-/+/<z:chebi fb="3" ids="16865">GABA</z:chebi>(A)-/- double knockout, CBS-/+ mice treated with muscimol and <z:mp ids='MP_0002169'>wild type</z:mp> (WT) mice </plain></SENT>
<SENT sid="5" pm="."><plain>Matrix Metalloproteinase (MMP-2, MMP-9), Tissue Inhibitor of Matrix Metalloproteinase (TIMP-3, TIMP-4), collagen-III and elastin levels were measured in whole brain by Western blot </plain></SENT>
<SENT sid="6" pm="."><plain>These results suggested an increase in Evan's blue permeability: CBS-/+&lt;<z:chebi fb="3" ids="16865">GABA</z:chebi>(A)-/-&lt;CBS-/+/<z:chebi fb="3" ids="16865">GABA</z:chebi>(A)-/- compared to WT mice </plain></SENT>
<SENT sid="7" pm="."><plain>Interestingly, in CBS-/+ mice treated with muscimol, <z:chebi fb="2" ids="33602">BBB</z:chebi> permeability was significantly decreased compared with the CBS-/+ group </plain></SENT>
<SENT sid="8" pm="."><plain>There was a decrease in the TIMP-4 protein expression level, whereas the TIMP-3 level increased in CBS-/+, <z:chebi fb="3" ids="16865">GABA</z:chebi>(A)-/-, and CBS-/+/<z:chebi fb="3" ids="16865">GABA</z:chebi>(A)-/- mice compared to the WT </plain></SENT>
<SENT sid="9" pm="."><plain>MMP-2 and MMP-9 expression significantly increased in <z:hpo ids='HP_0000001'>all</z:hpo> the groups compared to the <z:mp ids='MP_0002169'>wild type</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>The results suggested that <z:chebi fb="0" ids="17230">Hcy</z:chebi> caused cerebral interstitial remodeling in brain by distorting the extracellular matrix, thus increasing the blood brain permeability; treatment with muscimol mitigated <z:chebi fb="2" ids="33602">BBB</z:chebi> permeability </plain></SENT>
</text></document>